IRulya Therapeutics/$IRLA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IRulya Therapeutics
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
- Ticker
- $IRLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 38
- Headquarters
- New Haven, United States
- Website
- irulya.com
IRLA Metrics
BasicAdvanced
$39M
-
-$51.81
1.26
-
Price and volume
Market cap
$39M
Beta
1.26
52-week high
$45.00
52-week low
$15.10
Average daily volume
84K
Financial strength
Current ratio
14.519
Quick ratio
14.233
Profitability
EBITDA (TTM)
-60.647
Effective tax rate (TTM)
2.29%
Management effectiveness
Return on assets (TTM)
-31.51%
Return on equity (TTM)
-153.84%
Valuation
Price to book
-1.1
Price to tangible book (TTM)
-1.1
Price to free cash flow (TTM)
-1.456
Free cash flow yield (TTM)
-68.69%
Free cash flow per share (TTM)
-26.33
Growth
Earnings per share change (TTM)
-76.55%
3-year earnings per share growth (CAGR)
-32.84%
What the Analysts think about IRLA
Analyst ratings (Buy, Hold, Sell) for IRulya Therapeutics stock.
Analyst projections of the future price of IRulya Therapeutics stock.
IRLA Financial Performance
Revenues and expenses
IRLA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.